Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Ontario, Canada.
Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Cancer Res Commun. 2023 Apr 25;3(4):697-708. doi: 10.1158/2767-9764.CRC-22-0403. eCollection 2023 Apr.
The interaction between neoplastic and stromal cells within a tumor mass plays an important role in cancer biology. However, it is challenging to distinguish between tumor and stromal cells in mesenchymal tumors because lineage-specific cell surface markers typically used in other cancers do not distinguish between the different cell subpopulations. Desmoid tumors consist of mesenchymal fibroblast-like cells driven by mutations stabilizing beta-catenin. Here we aimed to identify surface markers that can distinguish mutant cells from stromal cells to study tumor-stroma interactions. We analyzed colonies derived from single cells from human desmoid tumors using a high-throughput surface antigen screen, to characterize the mutant and nonmutant cells. We found that CD142 is highly expressed by the mutant cell populations and correlates with beta-catenin activity. CD142-based cell sorting isolated the mutant population from heterogeneous samples, including one where no mutation was previously detected by traditional Sanger sequencing. We then studied the secretome of mutant and nonmutant fibroblastic cells. PTX3 is one stroma-derived secreted factor that increases mutant cell proliferation via STAT6 activation. These data demonstrate a sensitive method to quantify and distinguish neoplastic from stromal cells in mesenchymal tumors. It identifies proteins secreted by nonmutant cells that regulate mutant cell proliferation that could be therapeutically.
Distinguishing between neoplastic (tumor) and non-neoplastic (stromal) cells within mesenchymal tumors is particularly challenging, because lineage-specific cell surface markers typically used in other cancers do not differentiate between the different cell subpopulations. Here, we developed a strategy combining clonal expansion with surface proteome profiling to identify markers for quantifying and isolating mutant and nonmutant cell subpopulations in desmoid tumors, and to study their interactions via soluble factors.
肿瘤块内的肿瘤细胞与基质细胞的相互作用在癌症生物学中起着重要作用。然而,由于在其他癌症中常用的谱系特异性细胞表面标志物通常不能区分不同的细胞亚群,因此区分间叶性肿瘤中的肿瘤细胞和基质细胞具有挑战性。硬纤维瘤由突变稳定β-连环蛋白的间充质成纤维细胞样细胞组成。在这里,我们旨在鉴定可区分突变细胞与基质细胞的表面标志物,以研究肿瘤-基质相互作用。我们使用高通量表面抗原筛选分析了源自人硬纤维瘤单细胞的克隆,以表征突变细胞和非突变细胞。我们发现 CD142 在突变细胞群中高度表达,并与β-连环蛋白活性相关。基于 CD142 的细胞分选从异质样本中分离出突变群体,包括先前通过传统桑格测序未检测到突变的样本。然后,我们研究了突变和非突变成纤维细胞的分泌组。PTX3 是一种基质衍生的分泌因子,通过 STAT6 激活增加突变细胞的增殖。这些数据表明了一种敏感的方法来定量和区分间叶性肿瘤中的肿瘤细胞和基质细胞。它鉴定了由非突变细胞分泌的调节突变细胞增殖的蛋白质,这些蛋白质可能具有治疗作用。
区分间叶性肿瘤中的肿瘤细胞(肿瘤)和非肿瘤细胞(基质)特别具有挑战性,因为在其他癌症中常用的谱系特异性细胞表面标志物通常不能区分不同的细胞亚群。在这里,我们开发了一种结合克隆扩增和表面蛋白质组谱分析的策略,以鉴定用于定量和分离硬纤维瘤中突变和非突变细胞亚群的标志物,并通过可溶性因子研究它们的相互作用。